Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 16 min ago
Peer-reviewedCC BY-NC-NDHepatology communications

Hepatocyte senescence in metabolic dysfunction–associated steatotic liver disease (MASLD)

  • Xinyue Pang1
  • Nan Geng2
  • Chenqi Lu2
  • Qianwen Zhao2
  • Junping Shi3
  • Yali Xiong2
  • Wenhao Li4
  • Jie Li1
4 affiliations
  1. 1Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China
  2. 2Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
  3. 3Department of Hepatology, The Affiliated Hospital, Institute of Hepatology and Metabolic Disease, Hangzhou Normal University, Hangzhou, Zhejiang, China
  4. 4Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK
Read full textPDFCite

Related

  1. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
    Mohammed Alfawaz, Dareen Bajamaan, Lama Alghamdi +7
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Efficacy of plant extracts for metabolic dysfunction-associated steatotic liver disease: a network meta-analysis
    Zhenghong Xie, Tianxing Chen
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  3. Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series
    Brandon J. Perumpail, Andrea Tou, Jennifer Panganiban
    JPGN reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Functional and Metabolic Correlates of Age- and Sex-Normalized Handgrip Strength in Children with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Mohit Kehar, Carolina Jimenez-Rivera, Leah Feret +3
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
    Journal of Clinical and Translational HepatologyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{pang2026hepatocyte,
  title = {{Hepatocyte senescence in metabolic dysfunction–associated steatotic liver disease (MASLD)}},
  author = {Xinyue Pang and Nan Geng and Chenqi Lu and Qianwen Zhao and Junping Shi and Yali Xiong and Wenhao Li and Jie Li},
  journal = {Hepatology communications},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13668295},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Hepatocyte senescence in metabolic dysfunction–associated steatotic liver disease (MASLD)
AU  - Xinyue Pang
AU  - Nan Geng
AU  - Chenqi Lu
AU  - Qianwen Zhao
AU  - Junping Shi
AU  - Yali Xiong
AU  - Wenhao Li
AU  - Jie Li
PY  - 2026
DA  - 2026/10/14
JO  - Hepatology communications
UR  - https://europepmc.org/article/PMC/PMC13668295
SN  - 2471-254X
ER  -